Longeveron Inc. (NASDAQ: LGVN) shares are moving higher on Wednesday afternoon following the circulation of a Zacks Small Cap Research report valuing the company at $15.10 per share.
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday.
The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&P 500 also fell, dropping, 0.34% to 5,034.17.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday.
The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The S&P 500 also fell, dropping, 0.74% to 5,013.98.